CPC
NVO

Congress Park Capital’s Novo Nordisk NVO Stock Holding History

Congress Park Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Buy
+4,225
New +$182K 0.05% 131

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Congress Park Capital's NVO Position: Q2 2026 in Review

Congress Park Capital opened a new position in Novo Nordisk (NVO) in Q2 2026: 4,225 shares worth $203K. The stake represents 0.05% of the portfolio and ranks #131 among its holdings.

580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Congress Park Capital held 4,225 shares of Novo Nordisk worth $203K as of Q2 2026.
  • Novo Nordisk was a new Congress Park Capital position in Q2 2026.
  • Novo Nordisk made up 0.05% of Congress Park Capital's portfolio in Q2 2026, its #131 holding.
  • 580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Congress Park Capital's 13F filing for Q2 2026, filed 14 Jul 2026.